ESR1 and breast cancer: In TNBC and HER2 + BC, AR expression increased tumor proliferation, while in ERα-positive BC, its role is ambiguous with either pro- or anti-proliferative effects, depending on the level of co-expressed ERα and the presence of the particular ligand [12–14, 38].